SUSTAIN 4 results showing superiority of semaglutide vs. Lantus presented as a poster at AACE – May 27, 2016

Novo Nordisk presented the results of the SUSTAIN 4 trial showing superior A1c reductions and weight loss with semaglutide vs. Sanofi’s Lantus (insulin glargine) today as a poster at AACE. We first saw data from this study at Novo Nordisk’s Capital Markets Day in November; results demonstrated A1c reductions of 1.2% with 0.5 mg semaglutide and 1.6% with 1.0 mg semaglutide vs. 0.8% with Lantus in 1,089 insulin-naïve patients with type 2 diabetes (baseline = 8.2%). Semaglutide also produced a significant weight benefit: weight loss of 3.5 kg and 5.2 kg with the two respective doses vs. 1.2 kg weight gain with Lantus (baseline = 93 kg). Semaglutide has demonstrated positive results against a range of comparators throughout the SUSTAIN program and should be submitted to the FDA in 4Q16 – see our coverage of Novo Nordisk’s 1Q16 update for more.  

-- by Emily Regier and Kelly Close